ID   SH2B1_RAT               Reviewed;         756 AA.
AC   Q62985; O55072;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-DEC-2020, entry version 139.
DE   RecName: Full=SH2B adapter protein 1;
DE   AltName: Full=FceRI gamma-chain-interacting protein SH2-B;
DE   AltName: Full=SH2 domain-containing protein 1B;
DE   AltName: Full=SH2-B PH domain-containing signaling mediator 1;
GN   Name=Sh2b1; Synonyms=Sh2-b, Sh2bpsm1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH FCER1G.
RC   TISSUE=Mast cell;
RX   PubMed=9636306; DOI=10.1038/nbt1295-1474;
RA   Osborne M.A., Dalton S., Kochan J.P.;
RT   "The yeast tribrid system -- genetic detection of trans-phosphorylated
RT   ITAM-SH2-interactions.";
RL   Biotechnology (N.Y.) 13:1474-1478(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, PHOSPHORYLATION, AND
RP   INTERACTION WITH JAK2.
RC   TISSUE=Kidney;
RX   PubMed=9343427; DOI=10.1128/mcb.17.11.6633;
RA   Rui L., Mathews L.S., Hotta K., Gustafson T.A., Carter-Su C.;
RT   "Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2
RT   involved in growth hormone signaling.";
RL   Mol. Cell. Biol. 17:6633-6644(1997).
RN   [3]
RP   TISSUE SPECIFICITY.
RX   PubMed=9742218; DOI=10.1042/bj3350103;
RA   Kotani K., Wilden P., Pillay T.S.;
RT   "SH2-Balpha is an insulin-receptor adapter protein and substrate that
RT   interacts with the activation loop of the insulin-receptor kinase.";
RL   Biochem. J. 335:103-109(1998).
RN   [4]
RP   INTERACTION WITH PDGFRA/B.
RX   PubMed=9694882; DOI=10.1074/jbc.273.33.21239;
RA   Rui L., Carter-Su C.;
RT   "Platelet-derived growth factor (PDGF) stimulates the association of SH2-
RT   Bbeta with PDGF receptor and phosphorylation of SH2-Bbeta.";
RL   J. Biol. Chem. 273:21239-21245(1998).
RN   [5]
RP   FUNCTION IN NGF SIGNALING, INTERACTION WITH NTRK1, AND PHOSPHORYLATION.
RX   PubMed=9856458; DOI=10.1016/s0896-6273(00)80620-0;
RA   Qian X., Riccio A., Zhang Y., Ginty D.D.;
RT   "Identification and characterization of novel substrates of Trk receptors
RT   in developing neurons.";
RL   Neuron 21:1017-1029(1998).
RN   [6]
RP   FUNCTION IN NGF SIGNALING, PHOSPHORYLATION AT SER-96, AND MUTAGENESIS OF
RP   SER-96.
RX   PubMed=10473609; DOI=10.1074/jbc.274.37.26485;
RA   Rui L., Herrington J., Carter-Su C.;
RT   "SH2-B, a membrane-associated adapter, is phosphorylated on multiple
RT   serines/threonines in response to nerve growth factor by kinases within the
RT   MEK/ERK cascade.";
RL   J. Biol. Chem. 274:26485-26492(1999).
RN   [7]
RP   FUNCTION IN JAK2 ACTIVATION, AND MUTAGENESIS OF ARG-555.
RX   PubMed=10377387; DOI=10.1073/pnas.96.13.7172;
RA   Rui L., Carter-Su C.;
RT   "Identification of SH2-bbeta as a potent cytoplasmic activator of the
RT   tyrosine kinase Janus kinase 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:7172-7177(1999).
RN   [8]
RP   FUNCTION, INTERACTION WITH JAK2, AND MUTAGENESIS OF ARG-555.
RX   PubMed=10757801; DOI=10.1128/mcb.20.9.3168-3177.2000;
RA   Rui L., Gunter D.R., Herrington J., Carter-Su C.;
RT   "Differential binding to and regulation of JAK2 by the SH2 domain and N-
RT   terminal region of SH2-bbeta.";
RL   Mol. Cell. Biol. 20:3168-3177(2000).
RN   [9]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH SH2B2.
RX   PubMed=11238898; DOI=10.1128/mcb.21.5.1613-1620.2001;
RA   Qian X., Ginty D.D.;
RT   "SH2-B and APS are multimeric adapters that augment TrkA signaling.";
RL   Mol. Cell. Biol. 21:1613-1620(2001).
RN   [10]
RP   INTERACTION WITH JAK1; JAK2 AND JAK3, AND PHOSPHORYLATION.
RX   PubMed=11751854; DOI=10.1074/jbc.m109165200;
RA   O'Brien K.B., O'Shea J.J., Carter-Su C.;
RT   "SH2-B family members differentially regulate JAK family tyrosine
RT   kinases.";
RL   J. Biol. Chem. 277:8673-8681(2002).
RN   [11]
RP   FUNCTION IN ACTIN REORGANIZATION, AND INTERACTION WITH RAC1.
RX   PubMed=11786545; DOI=10.1074/jbc.m111138200;
RA   Diakonova M., Gunter D.R., Herrington J., Carter-Su C.;
RT   "SH2-Bbeta is a Rac-binding protein that regulates cell motility.";
RL   J. Biol. Chem. 277:10669-10677(2002).
RN   [12]
RP   INTERACTION WITH FGFR3.
RX   PubMed=11827956; DOI=10.1074/jbc.m102777200;
RA   Kong M., Wang C.S., Donoghue D.J.;
RT   "Interaction of fibroblast growth factor receptor 3 and the adapter protein
RT   SH2-B. A role in STAT5 activation.";
RL   J. Biol. Chem. 277:15962-15970(2002).
RN   [13]
RP   PHOSPHORYLATION AT TYR-439 AND TYR-494, AND MUTAGENESIS OF TYR-439 AND
RP   TYR-494.
RX   PubMed=12551917; DOI=10.1074/jbc.m210765200;
RA   O'Brien K.B., Argetsinger L.S., Diakonova M., Carter-Su C.;
RT   "YXXL motifs in SH2-Bbeta are phosphorylated by JAK2, JAK1, and platelet-
RT   derived growth factor receptor and are required for membrane ruffling.";
RL   J. Biol. Chem. 278:11970-11978(2003).
RN   [14]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-231 AND LEU-233.
RX   PubMed=15082760; DOI=10.1128/mcb.24.9.3633-3647.2004;
RA   Chen L., Carter-Su C.;
RT   "Adapter protein SH2-B beta undergoes nucleocytoplasmic shuttling:
RT   implications for nerve growth factor induction of neuronal
RT   differentiation.";
RL   Mol. Cell. Biol. 24:3633-3647(2004).
RN   [15]
RP   FUNCTION IN GDNF SIGNALING, AND INTERACTION WITH RET.
RX   PubMed=16569669; DOI=10.1242/jcs.02845;
RA   Zhang Y., Zhu W., Wang Y.G., Liu X.J., Jiao L., Liu X., Zhang Z.H.,
RA   Lu C.L., He C.;
RT   "Interaction of SH2-Bbeta with RET is involved in signaling of GDNF-induced
RT   neurite outgrowth.";
RL   J. Cell Sci. 119:1666-1676(2006).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Adapter protein for several members of the tyrosine kinase
CC       receptor family. Involved in multiple signaling pathways mediated by
CC       Janus kinase (JAK) and receptor tyrosine kinases, including the
CC       receptors of insulin (INS), insulin-like growth factor I (IGF1), nerve
CC       growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial
CC       cell line-derived neurotrophic factor (GDNF), platelet-derived growth
CC       factor (PDGF) and fibroblast growth factors (FGFs). In growth hormone
CC       (GH) signaling, autophosphorylated ('Tyr-813') JAK2 recruits SH2B1,
CC       which in turn is phosphorylated by JAK2 on tyrosine residues. These
CC       phosphotyrosines form potential binding sites for other signaling
CC       proteins. GH also promotes serine/threonine phosphorylation of SH2B1
CC       and these phosphorylated residues may serve to recruit other proteins
CC       to the GHR-JAK2-SH2B1 complexes, such as RAC1. In leptin (LEP)
CC       signaling, binds to and potentiates the activation of JAK2 by globally
CC       enhancing downstream pathways. In response to leptin, binds
CC       simultaneously to both, JAK2 and IRS1 or IRS2, thus mediating formation
CC       of a complex of JAK2, SH2B1 and IRS1 or IRS2. Mediates tyrosine
CC       phosphorylation of IRS1 and IRS2, resulting in activation of the PI 3-
CC       kinase pathway. Acts as positive regulator of NGF-mediated activation
CC       of the Akt/Forkhead pathway; prolongs NGF-induced phosphorylation of
CC       AKT1 on 'Ser-473' and AKT1 enzymatic activity. Enhances the kinase
CC       activity of the cytokine receptor-associated tyrosine kinase JAK2 and
CC       of other receptor tyrosine kinases, such as FGFR3 and NTRK1. For JAK2,
CC       the mechanism seems to involve dimerization of both, SH2B1 and JAK2.
CC       Enhances RET phosphorylation and kinase activity. Isoforms seem to be
CC       differentially involved in IGF-I and PDGF-induced mitogenesis (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:10377387,
CC       ECO:0000269|PubMed:10473609, ECO:0000269|PubMed:10757801,
CC       ECO:0000269|PubMed:11238898, ECO:0000269|PubMed:11786545,
CC       ECO:0000269|PubMed:16569669, ECO:0000269|PubMed:9343427,
CC       ECO:0000269|PubMed:9856458}.
CC   -!- SUBUNIT: Self-associates. Homopentamer. Forms a heteromultimeric
CC       complex with SH2B2. Interacts with SH2B2. Isoform 1 interacts via its
CC       SH2 domain with JAK2. Isoform 2 interacts via its SH2 domain and its N-
CC       terminus with JAK2; the SH2 domain is required for the major
CC       interaction with JAK2 phosphorylated on tyrosine residues; the N-
CC       terminus provides a low-affinity binding to JAK2 independent of JAK2
CC       phosphorylation. Isoform 1 interacts via its SH2 domain with INSR; the
CC       interaction requires receptor activation. Isoform 1 interacts with
CC       IGF1R; the interaction requires receptor activation. Isoform 2
CC       interacts via its SH2 domain with FGFR3. Isoform 2 interacts with RET;
CC       the interaction requires RET kinase activity. Isoform 2 interacts with
CC       RAC1. Isoform 2 interacts with PDGFRA and/or PDGFRB; the interaction
CC       requires receptor activation. Interacts with ISR1 and ISR2. Probably
CC       part of a complex consisting of INSR, ISR1 and SH2B1. Probably part of
CC       a ternary complex consisting of SH2B1, JAK2 and ISR1 or ISR2 (By
CC       similarity). May interact with FCER1G. Interacts (via SH2 domain) with
CC       NTRK1 (phosphorylated). {ECO:0000250, ECO:0000269|PubMed:10757801,
CC       ECO:0000269|PubMed:11238898, ECO:0000269|PubMed:11751854,
CC       ECO:0000269|PubMed:11786545, ECO:0000269|PubMed:11827956,
CC       ECO:0000269|PubMed:16569669, ECO:0000269|PubMed:9343427,
CC       ECO:0000269|PubMed:9636306, ECO:0000269|PubMed:9694882,
CC       ECO:0000269|PubMed:9856458}.
CC   -!- INTERACTION:
CC       Q62985; P07949: RET; Xeno; NbExp=3; IntAct=EBI-7395583, EBI-2480756;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15082760}. Membrane
CC       {ECO:0000305|PubMed:15082760}. Nucleus {ECO:0000269|PubMed:15082760}.
CC       Note=Shuttles between the nucleus and the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q62985-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q62985-2; Sequence=VSP_032045;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is ubiquitously expressed. Expressed in
CC       epididymal adipose tissue, liver and skeletal muscle.
CC       {ECO:0000269|PubMed:9742218}.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to treatment with
CC       growth hormone (GH), IFN-gamma (IFNG), BDNF, PDGF and FGF.
CC       Phosphorylated on tyrosine residues by JAK2 and JAK1. Phosphorylated on
CC       multiple serine and threonine residues in response to treatment with
CC       NGF. Phosphorylated on serine residues. {ECO:0000269|PubMed:10473609,
CC       ECO:0000269|PubMed:11751854, ECO:0000269|PubMed:12551917,
CC       ECO:0000269|PubMed:9343427, ECO:0000269|PubMed:9856458}.
CC   -!- SIMILARITY: Belongs to the SH2B adapter family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U57391; AAC52601.1; -; mRNA.
DR   EMBL; AF047577; AAC04575.1; -; mRNA.
DR   RefSeq; NP_001041645.1; NM_001048180.1.
DR   RefSeq; NP_604451.2; NM_134456.3. [Q62985-1]
DR   RefSeq; XP_006230415.1; XM_006230353.3. [Q62985-1]
DR   RefSeq; XP_006230416.1; XM_006230354.3. [Q62985-1]
DR   SMR; Q62985; -.
DR   BioGRID; 250140; 5.
DR   IntAct; Q62985; 37.
DR   MINT; Q62985; -.
DR   STRING; 10116.ENSRNOP00000066048; -.
DR   iPTMnet; Q62985; -.
DR   PaxDb; Q62985; -.
DR   PRIDE; Q62985; -.
DR   Ensembl; ENSRNOT00000074274; ENSRNOP00000066048; ENSRNOG00000049181. [Q62985-1]
DR   GeneID; 89817; -.
DR   KEGG; rno:89817; -.
DR   CTD; 25970; -.
DR   RGD; 620132; Sh2b1.
DR   eggNOG; ENOG502QT43; Eukaryota.
DR   GeneTree; ENSGT00950000183191; -.
DR   InParanoid; Q62985; -.
DR   OMA; SSTLMPF; -.
DR   OrthoDB; 556279at2759; -.
DR   PhylomeDB; Q62985; -.
DR   Reactome; R-RNO-1170546; Prolactin receptor signaling.
DR   Reactome; R-RNO-982772; Growth hormone receptor signaling.
DR   Reactome; R-RNO-983231; Factors involved in megakaryocyte development and platelet production.
DR   PRO; PR:Q62985; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000049181; Expressed in skeletal muscle tissue and 21 other tissues.
DR   ExpressionAtlas; Q62985; baseline and differential.
DR   Genevisible; Q62985; RN.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005068; F:transmembrane receptor protein tyrosine kinase adaptor activity; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0030032; P:lamellipodium assembly; ISO:RGD.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISO:RGD.
DR   GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; ISO:RGD.
DR   GO; GO:2000278; P:regulation of DNA biosynthetic process; ISO:RGD.
DR   CDD; cd10346; SH2_SH2B_family; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR015012; Phe_ZIP.
DR   InterPro; IPR036290; Phe_ZIP_sf.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR030523; SH2B.
DR   InterPro; IPR030521; SH2B1.
DR   InterPro; IPR035057; SH2B1_SH2.
DR   PANTHER; PTHR10872; PTHR10872; 1.
DR   PANTHER; PTHR10872:SF3; PTHR10872:SF3; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF08916; Phe_ZIP; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF109805; SSF109805; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasm; Membrane; Methylation; Nucleus;
KW   Phosphoprotein; Reference proteome; SH2 domain.
FT   CHAIN           1..756
FT                   /note="SH2B adapter protein 1"
FT                   /id="PRO_0000323611"
FT   DOMAIN          247..376
FT                   /note="PH"
FT   DOMAIN          527..625
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   REGION          1..555
FT                   /note="Interaction with JAK2 (low-affinity binding;
FT                   independent of JAK2 phosphorylation)"
FT   REGION          24..85
FT                   /note="Required for self-association"
FT                   /evidence="ECO:0000250"
FT   REGION          85..196
FT                   /note="Interaction with RAC1"
FT                   /evidence="ECO:0000269|PubMed:11786545"
FT   REGION          100..243
FT                   /note="Required for NGF signaling"
FT   REGION          224..233
FT                   /note="Required for nuclear localization"
FT   MOD_RES         88
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91ZM2"
FT   MOD_RES         96
FT                   /note="Phosphoserine; by MAPK1 or MAPK3; in vitro"
FT                   /evidence="ECO:0000269|PubMed:10473609"
FT   MOD_RES         270
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NRF2"
FT   MOD_RES         417
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91ZM2"
FT   MOD_RES         420
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91ZM2"
FT   MOD_RES         439
FT                   /note="Phosphotyrosine; by JAK1, JAK2 and PDGFR"
FT                   /evidence="ECO:0000269|PubMed:12551917"
FT   MOD_RES         494
FT                   /note="Phosphotyrosine; by JAK1, JAK2"
FT                   /evidence="ECO:0000269|PubMed:12551917"
FT   VAR_SEQ         632..756
FT                   /note="ERSTSRDPTQPSEPPPWTDPPHPGAEEASGAPEVAAATAAAAKERQEKEKAG
FT                   GGGVQEELVPMAELVPMAELEEAIAPGTEAQGGAGSSGDLEVSLMVQLQQLPLGGNGEE
FT                   GGHPRAINNQYSFV -> GREQAGSHAGVCEGDRCYPDASSTFLPFGASDCVTEHFP
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9343427"
FT                   /id="VSP_032045"
FT   MUTAGEN         96
FT                   /note="S->A: Reduces in vitro phosphorylation by MAPK1
FT                   and/or MAPK3."
FT                   /evidence="ECO:0000269|PubMed:10473609"
FT   MUTAGEN         231
FT                   /note="L->A: Abolishes nuclear localization; when
FT                   associated with A-233."
FT                   /evidence="ECO:0000269|PubMed:15082760"
FT   MUTAGEN         233
FT                   /note="L->A: Abolishes nuclear localization; when
FT                   associated with A-231."
FT                   /evidence="ECO:0000269|PubMed:15082760"
FT   MUTAGEN         439
FT                   /note="Y->F: Fails to enhance GH-induced membrane ruffling;
FT                   when associated with F-494."
FT                   /evidence="ECO:0000269|PubMed:12551917"
FT   MUTAGEN         439
FT                   /note="Y->F: Reduces phosphorylation by JAK1, JAK2 and
FT                   PDGFRA."
FT                   /evidence="ECO:0000269|PubMed:12551917"
FT   MUTAGEN         494
FT                   /note="Y->F: Fails to enhance GH-induced membrane ruffling;
FT                   when associated with F-439."
FT                   /evidence="ECO:0000269|PubMed:12551917"
FT   MUTAGEN         494
FT                   /note="Y->F: Reduces phosphorylation by JAK1 and JAK2."
FT                   /evidence="ECO:0000269|PubMed:12551917"
FT   MUTAGEN         555
FT                   /note="R->E: Reduces interaction with JAK2 and abolishes
FT                   JAK2 kinase activity; reduces GH-stimulated cell motility;
FT                   abolishes interaction with PDGFRA."
FT                   /evidence="ECO:0000269|PubMed:10377387,
FT                   ECO:0000269|PubMed:10757801"
FT   CONFLICT        211
FT                   /note="R -> K (in Ref. 2; AAC04575)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   756 AA;  79637 MW;  D4FCF3086CF3DFE0 CRC64;
     MNGAPSPEDG VFPSPPALPP PPPPSWQEFC ESHARAAALD LARRFRLYLA SHPQYAEPGA
     EAAFSGRFAE LFLQHFEAEV ARASGSLSPP VLAPLSPGVE IPPSHDLSLE SCRVGGPLAV
     LGPSRSSEDL AGPLPSSVSS STTSSKPKLK KRFSLRSVGR SVRGSVRGIL QWRGAVESPS
     QAGPLETTSG PPVLGGNSNS NSSGGAGTVG RALANDGTSP GERWTHRFER LRLSRGGGTL
     RDGAGVIQRE ELLSFMGAEE AAPDPAGVGR GGGAAGLTSG GGGQPQWQKC RLLLRSEGEG
     GGGSRLEFFV PPKASRPRLS IPCSTITDVR TATALEMPDR ENTFVVKVEG PSEYILETTD
     ALHVKAWVSD IQECLSPGPC PAISPRPMTL PLAPGTSFLT KDNTESLELP CLNHSESLPS
     QDLLLGPSES NDRLSQGAYG GLSDRPSASF SPSSASIAAS HFDSMELLPP ELPPRIPIEE
     GPPAGTVHPL STPYPPLDTP EAATGSFLFQ GEAEGGEGDQ PLSGYPWFHG MLSRLKAAQL
     VLEGGTSSHG VFLVRQSETR RGEYVLTFNF QGKAKHLRLS LNEEGQCRVQ HLWFQSIFDM
     LEHFRVHPIP LESGGSSDVV LVSYVPSQRQ QERSTSRDPT QPSEPPPWTD PPHPGAEEAS
     GAPEVAAATA AAAKERQEKE KAGGGGVQEE LVPMAELVPM AELEEAIAPG TEAQGGAGSS
     GDLEVSLMVQ LQQLPLGGNG EEGGHPRAIN NQYSFV
//
